Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 29;1(6):463-474.
doi: 10.36518/2689-0216.1228. eCollection 2020.

Covid-19: Race For A Vaccine

L Hayley Burgess  1 , Jason J Braithwaite  2   3 , Emily Singleton  2   4 , Aaron M Young  1 , Mandelin K Cooper  1
Affiliations
Review

Covid-19: Race For A Vaccine

L Hayley Burgess et al. HCA Healthc J Med. .

Abstract

Description The world is in the midst of a pandemic from COVID-19, a disease caused by the virus SARS-CoV-2. Despite broad mitigation efforts, new cases continue with 74 million cases and 1.6 million deaths worldwide. Regardless of previous research efforts, there is no commercially available vaccine for any coronavirus. Novel vaccine development has historically taken at least 10 years from discovery to availability with only a 6% market entry probability. With the global impact, there is an urgency to expedite a vaccine to protect the population. The U.S. government launched Operation Warp Speed with the goal to produce and deliver 300 million doses of safe and effective vaccines by January 2021. Efforts toward this goal have included coordinated government agency support, parallel clinical trial deployment, de-risking manufacturing earlier in the development process and real-time U.S. Food & Drug Administration evaluation of the safety and efficacy data. Safety is a priority and key analysis has not been eliminated during the compressed timeframe. The two frontrunner candidates show promising efficacy rates for preventing COVID-19 with Moderna reporting 94.1% efficacy and Pfizer reporting 95.0% efficacy. Despite the herculean efforts by scientists to develop an effective vaccine in such a short timeframe, several national surveys suggest that public confidence in these vaccines is low with less than 50% of the survey respondents willing to be vaccinated. According to experts, the U.S. needs the vaccine to be at least 70-80% effective and a 70-80% vaccination rate in order to return to normal. Significant education and promotion is planned in coordination with the Centers for Disease Control.

Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2; coronavirus infection; epidemic; immunization; messenger RNA; pandemic; patient safety; vaccines; viral vaccines/adverse effects.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest The authors declare they have no conflicts of interest.

Figures

Figure 1
Figure 1
Traditional vs. Accelerated Vaccine Development Timeline for COVID-19. Adapted from Operation Warp Speed Accelerated Process.
See this image and copyright information in PMC

References

    1. Johns Hopkins Coronavirus Resource Center. [Accessed December 28, 2020]. https://coronavirus.jhu.edu/map.html .
    1. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. - DOI - PMC - PubMed
    1. US Department of Defense. Coronavirus: Operation Warp Speed. [Accessed December 17, 2020]. https://www.defense.gov/Explore/Spotlight/Coronavirus/Operation-Warp-Speed/
    1. World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand... Published December 29, 2020.
    1. Hinton DM. Pfizer-BioNTech COVID-19 Vaccine: Letter of EUA Authorization. US Food and Drug Administration; https://www.fda.gov/media/144412/download Published December 11, 2020.

LinkOut - more resources